Comparing Angiotensin II and Noradrenaline to Reduce Kidney Injury After Cardiac Surgery Using Cardiopulmonary Bypass

What this Trial Is About

Researchers are evaluating the use of angiotensin II compared to norepinephrine as a primary vasopressor in patients undergoing cardiac surgery to see if angiotensin II can reduce the occurrence of moderate to severe acute kidney injury AKI. AKI is common after cardiac surgery and is linked to increased complications and mortality. Current treatments like norepinephrine have side effects and may become less effective in vasoplegic shock, a condition often seen after such surgeries. Participants will receive either angiotensin II or norepinephrine through intravenous infusion via a central line, with doses adjusted frequently to maintain a target mean arterial pressure above 65 mmHg. The study includes patients undergoing cardiac surgery with cardiopulmonary bypass and will compare these two vasopressors in this setting. The trial includes a randomized, quadruple-masked design to assess the impact of angiotensin II as a primary vasopressor. During the study, participants will be closely monitored for kidney function and other health outcomes. Researchers will measure the rate of moderate to severe AKI or death within 72 hours after surgery as the main outcome. Additional assessments include kidney events up to 90 days and chronic kidney injury progression up to 120 days post-surgery. The study includes detailed monitoring of vital signs, laboratory tests, and safety throughout the treatment and follow-up periods.

Reducing Cardiac-surgery Associated Acute Kidney Injury Occurence by Administering Angiotensin II